Biocon Biologics, Viatris launch products for sugar control in US

By Pallavi Dubey | NT

Bengaluru: Viatris Inc. (VTRS) and  Biocon Biologics Ltd. announced the US launch  of Semglee injection, a  branded product, and Insulin Glargine injection, an  unbranded product, to help  control high blood sugar in  adult and pediatric patients  with type 1 and type 2 diabetes.

“At Biocon Biologics we  are committed to expanding access to high-quality,  affordable biologics to  patients worldwide. The  launch of our interchangeable biosimilar insulin  glargine in the US by our  partner Viatris is in line  with our aspiration to provide biosimilar insulins to  ‘one in five insulin-dependent people with diabetes,  globally. This is indeed a  landmark event and we  believe it will allow us to  improve accessibility, availability and adoption of biosimilars in the US for the  benefit of patients and the  overall healthcare system.”  Shreehas Tambe, Deputy  CEO, Biocon Biologics.

To further expand access to insulins, Viatris  has established a range of  options to help patients, including the patient Assistance Programme, which  may provide free medicine  to eligible patients with financial problems.